Skip to main content
. 2019 Jun 14;49(10):1114–1120. doi: 10.1111/hepr.13362

Figure 2.

Figure 2

Sustained virologic response rate at 12 weeks after end of treatment (SVR12) with elbasvir/grazoprevir decreased markedly among 353 patients with hepatitis C virus (HCV) genotype 1 when there was a history of direct‐acting antiviral (DAA) therapy or a non‐structural protein (NS)5A double mutation.